Dr. Reddy's Laboratories introduces Colchicine tablets in US market

On Friday, Dr. Reddy's Laboratories and its subsidiaries informed the bourses, after-market hours that the company launched Colchicine tablets USP in the US markets. The drug is available in 0.6 mg tablets in bottle count sizes of 30s and 100s.

Colchicine tablets USP is the therapeutic equivalent generic version of Colcrys (colchicine) tablets, 0.6 mg, which are approved by United States Food and Drug Administration (USFDA). According to MAT data from IMS Health and Quintiles (IQVIA) for the most recent twelve-month ending in March 2020, the Colcrys brand and generic market had US sales of about US$ 491 million.

Dr Reddy's Laboratories is an integrated pharmaceutical company offering a portfolio of products and services comprising APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations, and spanning across major markets such as India, USA, Russia and CIS countries, and Europe.

On Friday, the stock of the company closed at Rs 4,008.95, down by 1.15 per cent or Rs 46.65 per share. The 52-week high is Rs 4,189.35 and the 52-week low is Rs 2,352 on BSE.